Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Midatech raises £6.3M through private investment round

Midatech Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, announced today it has raised £6.3 million through a private investment round.

5 Jan 2012

IHoP may play a critical role in type 1 diabetes

Researchers at Wake Forest Baptist Medical Center's Institute for Regenerative Medicine and colleagues have discovered a new protein that may play a critical role in how the human body regulates blood sugar levels.

5 Jan 2012

Weight loss surgery can improve blood sugar control in diabetes patients

Weight loss surgery is not a cure for type 2 diabetes, but it can improve blood sugar control, according to a new study published in the British Journal of Surgery. Whereas some previous studies have claimed that up to 80 per cent of diabetes patients have been cured following gastric bypass surgery, researchers at Imperial College London found that only 41 per cent of patients achieve remission using more stringent criteria.

5 Jan 2012

Arrowhead receives FDA IND approval for Adipotide obesity drug

Arrowhead Research Corporation, a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application (IND) for its first obesity drug candidate, Adipotide, was accepted by the U.S. Food and Drug Administration allowing the initiation of a clinical trial to test the safety of the compound.

5 Jan 2012

Medtronic introduces mySentry Remote Glucose Monitor in the U.S.

Today, Medtronic, Inc. announced U.S. Food and Drug Administration (FDA) approval and U.S. market launch of the first-of-its-kind mySentry Remote Glucose Monitor, which allows a parent or caregiver to monitor from another room a patient's MiniMed Paradigm REAL-Time Revel System.

From Medtronic 4 Jan 2012

Weight loss surgery cuts risk of heart attacks, strokes: Study

A new study shows that weight loss surgery clearly cuts the risk of heart attacks, strokes and death from cardiovascular disease. But the research also raises questions regarding which patients benefit the most from surgery.

4 Jan 2012

Researchers discover culprit that leads from heart failure to diabetes

Either heart failure or diabetes alone is bad enough, but oftentimes the two conditions seem to go together. Now, researchers reporting in the January Cell Metabolism appear to have found the culprit that leads from heart failure to diabetes and perhaps a novel way to break that metabolic vicious cycle.

4 Jan 2012

Osiris provides update on Prochymal Phase 2 trial for type 1 diabetes

Osiris Therapeutics, Inc., today provided an update on its Phase 2 trial evaluating Prochymal, a formulation of adult mesenchymal stem cells (MSCs), in patients with newly diagnosed type 1 diabetes.

4 Jan 2012

BioMarin to initiate BMN-111 Phase 1 trial in achondroplasia

BioMarin Pharmaceutical Inc. announced today that the Investigational New Drug (IND) application for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia is active.

4 Jan 2012

Hormone Adiponectin linked to dementia in women: Study

New research has shown that there may be a possible connection between a hormone found in body fat and the risk of dementia, adding to the growing evidence on the potential link between the condition and diabetes.

3 Jan 2012

Adiponectin may play a role in development of all-cause dementia and AD in women

A hormone derived from visceral fat called adiponectin may play a role as a risk factor for development of all-cause dementia and Alzheimer disease (AD) in women, according to a study published Online First by the Archives of Neurology, one of the JAMA/Archives journals.

3 Jan 2012

Four or more coffees reduce risk of womb cancer

According to a new study drinking four or more cups of coffee a day may reduce risk of developing endometrial cancer or womb cancer by almost 25 per cent.

1 Jan 2012

Mother's milk for healthy growth

A PhD project from LIFE - the Faculty of Life Sciences at the University of Copenhagen has shown that breastfed children follow a different growth pattern than non-breastfed children. Breastfeeding lowers the levels of the growth hormones IGF-I and insulin in the blood, which means that growth is slightly slower. This is believed to reduce the risk of overweight and diabetes later in life.

21 Dec 2011

Scientists discover missing link between body's biological clock and sugar metabolism system

Scientists have discovered a missing link between the body's biological clock and sugar metabolism system, a finding that may help avoid the serious side effects of drugs used for treating asthma, allergies and arthritis.

20 Dec 2011

EMA CHMP recommends approval for BioMarin's Novato manufacturing facility expansion

BioMarin Pharmaceutical Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval for the company's manufacturing facility expansion in Novato, CA.

19 Dec 2011

State roundup: Florida awaits Medicaid waiver news

Now, nurses regularly do everything from give insulin shots to empty urinary catheter bags. At the same time, state budget cuts mean the number of school nurses in California is shrinking. As a result, nurses say, they are responsible for more students every year and are largely consumed with keeping "medically fragile" children in class.

16 Dec 2011

JHN to initiate new Phase I immunotherapy trial in glioblastoma

Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.

15 Dec 2011